Grazia Rutigliano

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/485372/grazia-rutigliano-publications-by-year.pdf

Version: 2024-04-03

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69 2,943 27 54 g-index

76 3,688 5.5 5.22 ext. papers ext. citations avg, IF L-index

| # | Paper | IF | Citations |
|----|---|--------------|-----------|
| 69 | Clinical Staging of Psychiatric Disorders: Its Utility in Mental Health Prevention 2022 , 37-51 | | |
| 68 | TAM-TAAR1 signalling protects against OGD-induced synaptic dysfunction in the entorhinal cortex. <i>Neurobiology of Disease</i> , 2021 , 151, 105271 | 7.5 | 3 |
| 67 | Thyroid disrupting effects of low-dose dibenzothiophene and cadmium in single or concurrent exposure: New evidence from a translational zebrafish model. <i>Science of the Total Environment</i> , 2021 , 769, 144703 | 10.2 | 1 |
| 66 | Developing and Validating an Individualized Clinical Prediction Model to Forecast Psychotic Recurrence in Acute and Transient Psychotic Disorders: Electronic Health Record Cohort Study. <i>Schizophrenia Bulletin</i> , 2021 , 47, 1695-1705 | 1.3 | О |
| 65 | Subacute Thyroiditis During the SARS-CoV-2 Pandemic. <i>Journal of the Endocrine Society</i> , 2021 , 5, bvab1: | 30 .4 | 4 |
| 64 | Lower speech connectedness linked to incidence of psychosis in people at clinical high risk. <i>Schizophrenia Research</i> , 2021 , 228, 493-501 | 3.6 | 7 |
| 63 | Tele-Mental Health for Reaching Out to Patients in a Time of Pandemic: Provider Survey and Meta-analysis of Patient Satisfaction. <i>JMIR Mental Health</i> , 2021 , 8, e26187 | 6 | 7 |
| 62 | Unconscious processing of subliminal stimuli in panic disorder: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 128, 136-151 | 9 | 3 |
| 61 | Portable technologies for digital phenotyping of bipolar disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2021 , 295, 323-338 | 6.6 | 3 |
| 60 | Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 6 |
| 59 | Acute oxytocin effects in inferring others' beliefs and social emotions in people at clinical high risk for psychosis. <i>Translational Psychiatry</i> , 2020 , 10, 203 | 8.6 | 2 |
| 58 | 3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 5 |
| 57 | Physiological Role of Thyroid Hormone in the Developing and Mature Heart 2020 , 13-22 | | |
| 56 | Depression and Cardiovascular Diseases 2020 , 281-295 | | |
| 55 | Exogenous 3-lodothyronamine Rescues the Entorhinal Cortex from EAmyloid Toxicity. <i>Thyroid</i> , 2020 , 30, 147-160 | 6.2 | 14 |
| 54 | T139. OXYTOCIN ENHANCES NEURAL EFFICIENCY IN INFERRING OTHERSISOCIAL EMOTIONS IN PEOPLE AT CLINICAL HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S283-S284 | 1.3 | 78 |
| 53 | ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. <i>Frontiers in Molecular Biosciences</i> , 2020 , 7, 588618 | 5.6 | 49 |

(2018-2020)

| 52 | Molecular Variants in Human Trace Amine-Associated Receptors and Their Implications in Mental and Metabolic Disorders. <i>Cellular and Molecular Neurobiology</i> , 2020 , 40, 239-255 | 4.6 | 12 |
|----|---|------|----|
| 51 | Non-Functional Trace Amine-Associated Receptor 1 Variants in Patients With Mental Disorders. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1027 | 5.6 | 7 |
| 50 | Unmet needs in patients with brief psychotic disorders: Too ill for clinical high risk services and not ill enough for first episode services. <i>European Psychiatry</i> , 2019 , 57, 26-32 | 6 | 25 |
| 49 | Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis. <i>Neuropsychopharmacology</i> , 2019 , 44, 1300-1309 | 8.7 | 17 |
| 48 | Depression and Cardiovascular Diseases 2019 , 1-15 | | |
| 47 | Transdiagnostic Individualized Clinically Based Risk Calculator for the Detection of Individuals at Risk and the Prediction of Psychosis: Model Refinement Including Nonlinear Effects of Age. <i>Frontiers in Psychiatry</i> , 2019 , 10, 313 | 5 | 15 |
| 46 | Involvement of single-nucleotide missense variants of TAAR1 in mental disorders. <i>European Neuropsychopharmacology</i> , 2019 , 29, S586-S587 | 1.2 | |
| 45 | F94. EFFECTS OF OXYTOCIN ON NEUROCHEMICAL METABOLITES IN PSYCHOSIS RISK. <i>Schizophrenia Bulletin</i> , 2019 , 45, S289-S290 | 1.3 | 78 |
| 44 | Neurochemical effects of oxytocin in people at clinical high risk for psychosis. <i>European Neuropsychopharmacology</i> , 2019 , 29, 601-615 | 1.2 | 4 |
| 43 | Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk and the Prediction of Psychosis: Second Replication in an Independent National Health Service Trust. <i>Schizophrenia Bulletin</i> , 2019 , 45, 562-570 | 1.3 | 53 |
| 42 | Novel thyroid hormones. <i>Endocrine</i> , 2019 , 66, 95-104 | 4 | 20 |
| 41 | Clinical-learning versus machine-learning for transdiagnostic prediction of psychosis onset in individuals at-risk. <i>Translational Psychiatry</i> , 2019 , 9, 259 | 8.6 | 17 |
| 40 | Gamma band oscillations in the early phase of psychosis: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 90, 381-399 | 9 | 25 |
| 39 | The complex relationship between self-reported 'personal recovery' and clinical recovery in schizophrenia. <i>Schizophrenia Research</i> , 2018 , 192, 108-112 | 3.6 | 28 |
| 38 | Diagnostic and Prognostic Significance of DSM-5 Attenuated Psychosis Syndrome in Services for Individuals at Ultra High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2018 , 44, 264-275 | 1.3 | 21 |
| 37 | Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives. <i>Psychological Medicine</i> , 2018 , 48, 1359-1 | 368 | 18 |
| 36 | Overexpression of endophilin A1 exacerbates synaptic alterations in a mouse model of Alzheimer's disease. <i>Nature Communications</i> , 2018 , 9, 2968 | 17.4 | 19 |
| 35 | S149. EFFECTS OF INTRANASAL OXYTOCIN ON RESTING CEREBRAL BLOOD FLOW IN PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018 , 44, S383-S383 | 1.3 | 78 |

| 34 | 34.2 IMPROVING THE DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN SECONDARY MENTAL HEALTH CARE. <i>Schizophrenia Bulletin</i> , 2018 , 44, S56-S57 | 1.3 | 78 |
|----|---|------|-----|
| 33 | T122. UNMET NEEDS IN PATIENTS WITH ACUTE TRANSIENT PSYCHOTIC DISORDERS (ATPD): ANALYSIS OF PATHWAYS TO CARE: AN 8 YEARS FOLLOW-UP STUDY. <i>Schizophrenia Bulletin</i> , 2018 , 44, S162-S163 | 1.3 | 78 |
| 32 | Long term outcomes of acute and transient psychotic disorders: The missed opportunity of preventive interventions. <i>European Psychiatry</i> , 2018 , 52, 126-133 | 6 | 25 |
| 31 | Semistructured Interview for Bipolar At Risk States (SIBARS). <i>Psychiatry Research</i> , 2018 , 264, 302-309 | 9.9 | 22 |
| 30 | An isoform-selective p38\(\text{mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease. \(\textit{Neurobiology of Aging, 2018, 70, 86-91}\) | 5.6 | 11 |
| 29 | Diagnostic and Prognostic Significance of Brief Limited Intermittent Psychotic Symptoms (BLIPS) in Individuals at Ultra High Risk. <i>Schizophrenia Bulletin</i> , 2017 , 43, 48-56 | 1.3 | 91 |
| 28 | Long-term validity of the At Risk Mental State (ARMS) for predicting psychotic and non-psychotic mental disorders. <i>European Psychiatry</i> , 2017 , 42, 49-54 | 6 | 82 |
| 27 | Cardiac actions of thyroid hormone metabolites. <i>Molecular and Cellular Endocrinology</i> , 2017 , 458, 76-81 | 4.4 | 25 |
| 26 | Bipolar Disorder With Psychotic Features and Ocular Toxoplasmosis: A Possible Pathogenetic Role of the Parasite?. <i>Journal of Nervous and Mental Disease</i> , 2017 , 205, 192-195 | 1.8 | 8 |
| 25 | Development and Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis. <i>JAMA Psychiatry</i> , 2017 , 74, 493-500 | 14.5 | 150 |
| 24 | Decreased lymphocyte dopamine transporter in romantic lovers. CNS Spectrums, 2017, 22, 290-294 | 1.8 | 8 |
| 23 | The Case for TAAR1 as a Modulator of Central Nervous System Function. <i>Frontiers in Pharmacology</i> , 2017 , 8, 987 | 5.6 | 60 |
| 22 | Formal thought disorder in people at ultra-high risk of psychosis. BJPsych Open, 2017, 3, 165-170 | 5 | 11 |
| 21 | Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma. <i>Psychiatry Research</i> , 2017 , 256, 359-364 | 9.9 | 34 |
| 20 | The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017 , 267, 285-294 | 5.1 | 27 |
| 19 | Improving Prognostic Accuracy in Subjects at Clinical High Risk for Psychosis: Systematic Review of Predictive Models and Meta-analytical Sequential Testing Simulation. <i>Schizophrenia Bulletin</i> , 2017 , 43, 375-388 | 1.3 | 82 |
| 18 | Deconstructing Pretest Risk Enrichment to Optimize Prediction of Psychosis in Individuals at Clinical High Risk. <i>JAMA Psychiatry</i> , 2016 , 73, 1260-1267 | 14.5 | 87 |
| 17 | The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. <i>Schizophrenia Bulletin</i> , 2016 , 42, 732-43 | 1.3 | 144 |

LIST OF PUBLICATIONS

| 16 | Prognosis of Brief Psychotic Episodes: A Meta-analysis. <i>JAMA Psychiatry</i> , 2016 , 73, 211-20 | 14.5 | 119 |
|----|---|-------|-----|
| 15 | Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis. <i>Schizophrenia Bulletin</i> , 2016 , 42, 1395-1406 | 1.3 | 106 |
| 14 | Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk: A Meta-analytical Stratification. <i>JAMA Psychiatry</i> , 2016 , 73, 113-20 | 14.5 | 270 |
| 13 | Neurobiological Models of Self-Disorders in Early Schizophrenia. <i>Schizophrenia Bulletin</i> , 2016 , 42, 874-8 | 301.3 | 31 |
| 12 | Insight in Psychiatry and Neurology: State of the Art, and Hypotheses. <i>Harvard Review of Psychiatry</i> , 2016 , 24, 214-28 | 4.1 | 8 |
| 11 | Peripheral oxytocin and vasopressin: Biomarkers of psychiatric disorders? A comprehensive systematic review and preliminary meta-analysis. <i>Psychiatry Research</i> , 2016 , 241, 207-20 | 9.9 | 93 |
| 10 | Social cognition in people with schizophrenia: a cluster-analytic approach. <i>Psychological Medicine</i> , 2016 , 46, 2717-29 | 6.9 | 42 |
| 9 | Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. <i>Journal of Affective Disorders</i> , 2016 , 203, 101-110 | 6.6 | 91 |
| 8 | At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. <i>World Psychiatry</i> , 2015 , 14, 322-32 | 14.4 | 172 |
| 7 | The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. <i>World Psychiatry</i> , 2014 , 13, 275-87 | 14.4 | 258 |
| 6 | P.8.b.014 Magnesium supply improves adherence to hypocaloric diets in women: effects on weight control competence [breliminary results. <i>European Neuropsychopharmacology</i> , 2014 , 24, S741-S742 | 1.2 | |
| 5 | Metabolic syndrome and major depression. CNS Spectrums, 2014, 19, 293-304 | 1.8 | 98 |
| 4 | The 5-HT6 receptor antagonism approach in Alzheimer's disease. <i>Drugs of the Future</i> , 2014 , 39, 133 | 2.3 | 7 |
| 3 | Major Depressive Disorder 2014 , 11-16 | | |
| 2 | P.2.d.040 Psychiatric patients carrying the CYP2C9*2 allele require lower doses of valproic acid to achieve target plasma levels. <i>European Neuropsychopharmacology</i> , 2013 , 23, S387 | 1.2 | |
| 1 | The Psychosis High-Risk State. <i>Key Issues in Mental Health</i> ,55-68 | | 1 |